Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

COVID-19 vaccine stocks gain as Biden expected to request new vaccine, recommended for all

Published 28/08/2023, 12:06
© Reuters

President Biden announced on Friday his intention to seek further funding from Congress to support the development of a new COVID-19 vaccine.

He indicated that he might request a universal vaccination, which would include both those who have previously been vaccinated and those who have not.

During his time in the Lake Tahoe region, President Biden was approached by a reporter on Friday for insights on the surge in COVID-19 cases and the emergence of a new variant.

"Yes, I can,” he said. "I signed off this morning on a proposal we have to present to Congress, a request for additional funding for a new vaccine that is necessary and effective."

"Tentatively, it is recommended that it will likely be recommended everybody get it no matter whether they’ve gotten it before or not."

It is notable that a funding request of $40 million, submitted to Congress by the White House on August 11, did not explicitly mention funding for Coronavirus-related matters.

According to a report in the Associated Press, the Biden administration is anticipating the development of a revised COVID-19 vaccine that specifically targets a particular variant of the omicron strain, known as XBB.1.5.

Shares in major COVID-19 vaccine makers – Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA), and Novavax (NASDAQ:NVAX) – were all trading modestly higher in pre-open Monday trade.

Latest comments

Oh no, not again...?
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.